Clinical Trial of Pancreatic Cancer in Stockholm.

Pancreatic Cancer Clinical Trial

— SPP  

Official title:

Prospective Populationbased Study on Pancreatic Cancer in Stockholm- Mutation Profiling Characteristics, Biobanking and Risk Factors.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02162823
• Other study ID #: 2006/1089-31/4
• Secondary ID: 2006/1089-31/4
• Status: Completed
• Start date: May 2007
• Est. completion date: February 2017

Study information

• Verified date: October 2023
• Source: Karolinska University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

SPP study includes incidence cases of pancreatic cancer in the Stockholm county region from 2007 to 2014. The purpose of SPP study is to estimate relative risk of pancreatic cancer in relation to snuff dipping, overweight/obesity, individual food items, food groups, dietary pattern and various nutrients; to estimate relative risk of pancreatic cancer in relation to exposure to nitrosamines, either endogenously or exogenously; to estimate relative risk of pancreatic cancer in relation to oral health and H.pylori infection and their interaction with ABO blood type; to estimation relative risk of pancreatic cancer in relation to hepatitis B or hepatitis C infection; to estimate relative risk of pancreatic cancer in relation to some genetic polymorphisms, either functional or being suggested in GWAS study; to estimate mutation profile in pancreatic cancer cases, and its correlation with environmental exposures, and the impacts on survival periods in pancreatic cancer patients.

The MeSH name is Carcinoma, Pancreatic Ductal

Description:

The SPP study is a prospective population-based case-control study. We include incident cases of pancreatic cancer in the Stockholm county region during 2008 to 2014. Controls are randomly selected from general population in the Stockholm region, and individually matched to cases by age and sex.

Cases selection. The criteria for cases selection including those are age less than 85 years, born in Sweden and presently living in the county of Stockholm. The cases of pancreatic cancer are first identified within the framework of the clinical healthcare system of the Stockholm County. Through a network, consisting of all surgical clinics and the only oncological clinic in the Stockholm county area, we were able to include a vast majority of cases diagnosed with radiological methods, he or she were asked to participate in the study. After informed consent is obtained from the patient, the study coordinator at the Karolinska University Hospital at Huddinge was notified. The coordinator will inform Statistics Sweden interviewer to interview the case patient. Further, after radiological diagnosis of pancreatic cancer, we try to retrieve a tumor biopsy for every case. In total around 30% of the cases are surgically resected and of the remaining 70% of the patients treated with a palliative intention and among which more than 80% are biopsied using fine needle aspiration (the remaining 20% not biopsied for practical reasons such as clinical deterioration), thus resulting in a total proportion of patients in which tumor tissue is retained of close to 90%.

Control selection. The control persons (non-cancer patients) are randomly identified via the Statistics Sweden. For each case, a gender- and age-matched (same birth year) control person will be identified randomly from the general population of the Stockholm County.

Data collection. Through professional interviewers from the Statistics Sweden, interviews were conducted concerning environmental factors with both cases and control persons. As soon as the study coordinator identified a case of pancreatic cancer and the patient has accepted to participate, Statistics Sweden is contacted about this patient's identify and location. Professional interviewers, blinded to the research hypotheses of the study, will then contact and go to the patient at home, at the hospital or wherever the patient is and perform the interview which is calculated to take around 1 hour and 15 minutes. The questionnaire contains items concerning demographics, socioeconomic factors, physical activity, height and weight history, tobacco and snuff use, dental health, earlier and concomitant diseases and medication history. A structured food frequency questionnaire, a modified version of a previously evaluated questionnaire, including 63 food and beverage items of interest, are used to evaluate dietary habits 20 years prior to interview.

Once a case has been identified, a set of up to 5 controls (same sex and birth year) from Stockholm general population will be selected by the Statistics Sweden. The control persons in the list are contacted by order, until a control person agrees to participate in our study. The interviewers will perform the interview in exactly the same way for the cases.

For each case and control, if they agree, 20 ml of blood are collected. The samples are separated into serum and cells (red and white together) and aliquot into 4 separate serum (for subsequent protein analysis) samples and 2 cell samples after Ficoll gradient (for subsequent DNA and RNA analysis) and immediately frozen to -80°C. Control persons that decline leaving a blood sample are instead offered to leave a saliva sample, from which DNA can be extracted and analyzed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 600
• Est. completion date: February 2017
• Est. primary completion date: February 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• pancreatic cancer patients that aged less than 85 years old born in Sweden living in Stockholm

• written informed consent

Exclusion Criteria:

• pancreatic cancer older than 85 years

• pancratic cancer younger than 18 years

• not willing to participate

Related Conditions & MeSH terms

• Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Procedure:
• Pancreatic Surgery
Surgical removal of the pancreatic tumour (cancer) in the intervention group

Locations

Country	Name	City	State
Sweden	Karolinska University Hospital, Gastrocentrum	Stockholm

Sponsors (1)

Lead Sponsor	Collaborator
Karolinska University Hospital

Country where clinical trial is conducted

Sweden, 

References & Publications (4)

Molina-Montes E, Coscia C, Gomez-Rubio P, Fernandez A, Boenink R, Rava M, Marquez M, Molero X, Lohr M, Sharp L, Michalski CW, Farre A, Perea J, O'Rorke M, Greenhalf W, Iglesias M, Tardon A, Gress TM, Barbera VM, Crnogorac-Jurcevic T, Munoz-Bellvis L, Domi — View Citation

Molina-Montes E, Van Hoogstraten L, Gomez-Rubio P, Lohr M, Sharp L, Molero X, Marquez M, Michalski CW, Farre A, Perea J, O'Rorke M, Greenhalf W, Ilzarbe L, Tardon A, Gress TM, Barbera VM, Crnogorac-Jurcevic T, Munoz-Bellvis L, Dominguez-Munoz E, Balsells — View Citation

Yu J, Ploner A, Kordes M, Lohr M, Nilsson M, de Maturana MEL, Estudillo L, Renz H, Carrato A, Molero X, Real FX, Malats N, Ye W. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma. Int J Cancer. 2021 Apr 15;148(8):2048-2058. — View Citation

Yu J, Song H, Ekheden I, Lohr M, Ploner A, Ye W. Gastric Mucosal Abnormality and Risk of Pancreatic Cancer: A Population-Based Gastric Biopsy Cohort Study in Sweden. Cancer Epidemiol Biomarkers Prev. 2021 Nov;30(11):2088-2095. doi: 10.1158/1055-9965.EPI-2 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Survival		5 years
Secondary	Factors influencing survival		5 years